Evidence map›Paper›PMID 39501043›Full record

ArticleScientific reports2024

A novel immunomodulating peptide with potential to complement oligodeoxynucleotide-mediated adjuvanticity in vaccination strategies.

Michael Agrez, Christopher Chandler, Kristofer J Thurecht, Nicholas L Fletcher, Feifei Liu, Gayathri Subramaniam, Christopher B Howard, Stephen Parker, Darryl Turner, Justyna Rzepecka and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Michael AgrezInterK Peptide Therapeutics Limited, Lane Cove West, NSW, Australia. michael.agrez@interk.com.au.
Christopher ChandlerAuspep Pty Limited, Melbourne, Australia.
Kristofer J ThurechtCentre for Advanced Imaging, University of Queensland, Brisbane, Australia.
Nicholas L FletcherCentre for Advanced Imaging, University of Queensland, Brisbane, Australia.
Feifei LiuCentre for Advanced Imaging, University of Queensland, Brisbane, Australia.
Gayathri SubramaniamCentre for Advanced Imaging, University of Queensland, Brisbane, Australia.
Christopher B HowardCentre for Advanced Imaging, University of Queensland, Brisbane, Australia.
Stephen ParkerInterK Peptide Therapeutics Limited, Lane Cove West, NSW, Australia.
Darryl TurnerConcept Life Sciences, Edinburgh, Scotland.
Justyna RzepeckaConcept Life Sciences, Edinburgh, Scotland.
Gavin KnoxConcept Life Sciences, Edinburgh, Scotland.
Anastasia NikaConcept Life Sciences, Edinburgh, Scotland.
Andrew M HallConcept Life Sciences, Edinburgh, Scotland.
Hayley GoodingConcept Life Sciences, Edinburgh, Scotland.
Laura GallagherConcept Life Sciences, Edinburgh, Scotland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of adjuvants to improve vaccination efficacy is a major unmet need. One approach is to augment the functionality of dendritic cells (DCs) by using Toll-like receptor-9 (TLR9) agonists such as cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODNs) as adjuvants. Another approach is adjuvant selection based on production of bioactive interleukin-12 (IL-12). We report a D-peptide isomer, designated D-15800, that induces monocyte differentiation to the DC phenotype in vitro and more effectively stimulates IL-12p70 production upon T cell receptor (TCR) activation than the L-isomer. In the absence of TCR activation and either IL-12p70 or interleukin-2 production, only D-15800 activates CD4

Indexed as

Adjuvants, ImmunologicDendritic CellsOligodeoxyribonucleotidesToll-Like Receptor 9VaccinationCD4-Positive T-LymphocytesCell DifferentiationHumansImmunomodulating AgentsInterferon-alphaInterleukin-12Killer Cells, NaturalMonocytesPeptidesAdjuvants, ImmunologicCPG-oligonucleotideImmunomodulating AgentsInterferon-alphaInterleukin-12OligodeoxyribonucleotidesPeptidesToll-Like Receptor 9

Identifiers

PMID39501043
PMCPMC11538426

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.